

1 **Anti-inflammatory, antinociceptive, antioxidant, and antimicrobial activities of**
 2 **hydroalcoholic extracts of *Witheringia solanacea* L'Hér**

3 **Actividad antiinflamatoria, antinociceptiva, antioxidante y antimicrobiana de**
 4 **extractos hidroalcohólicos de *Witheringia solanacea* L'Hér**

6 **Running title: Pharmacological activities of *Witheringia solanacea***

8 **Cristina Herrera^{1*}, Fabián Delgado-Rodríguez¹, Navilla Apú¹, Verónica Madrigal-Gamboa², Marta Porras¹**

10 ¹Pharmaceutical Research Institute (INIFAR), School of Pharmacy, University of Costa Rica, 11501-2060 San José, Costa Rica.

11 ²School of Pharmacy, University of Costa Rica, 11501-2060 San José, Costa Rica.

12 *E-mail address: cristina.herrera@ucr.ac.cr

14 *Corresponding author address:

15 Pharmaceutical Research Institute (INIFAR), School of Pharmacy, University of Costa Rica, 11501-2060 San José, Costa Rica.

16 Tel: +506 25118330

17 **42 number of pages, 9 figures, and 2 tables**

18 **Institutional e-mail of the authors:**

Author	Institutional e-mail (mandatory)	Other e-mail (gmail, yahoo, etc.)	ORCID (0000-1111-2222-3333)
Cristina Herrera	cristina.herrera@ucr.ac.cr	cristina.herreraarias@gmail.com	0000-0001-5555-2302
Fabián Delgado-Rodríguez	fabian.delgadorodriguez@ucr.ac.cr		0000-0002-8268-7162
Navilla Apú	navilla.apu@ucr.ac.cr	naviapu21@gmail.com	0000-0002-6848-7252
Verónica Madrigal-Gamboa	veronica.madrigalgamboa@ucr.ac.cr	vmadrigal@gmail.com	0000-0003-3340-555X
Marta Porras	marta.porras@ucr.ac.cr		0000-0001-5626-1005

19 **Contribution Details**

20

Contribution	Herrera C	Delgado- Rodríguez F	Apú N	Madriral- Gamboa V	Porras M
Concepts or Ideas	X	X			
Design	X	X			
Definition of intellectual content	X	X			
Literature search	X	X			
Experimental studies	X	X	X	X	X
Data acquisition	X	X	X	X	
Data analysis	X	X			
Statistical analysis	X	X			
Manuscript preparation	X	X			
Manuscript editing	X	X	X	X	X
Manuscript review	X	X	X	X	X

21

22 **ABBREVIATIONS:** DPPH: 2,2-diphenyl-1-picrylhydrazyl assay; DW: dry weight; E%: percentage of edema;

23 EDTAE: ethylenediaminetetraacetic acid equivalents; F1: fruit extract from Mora; F2: fruit extract from Puerto

24 Jiménez; FICA: ferrous iron chelating activity assay; FRAP: ferric reducing antioxidant power assay; GAE: gallic

25 acid equivalents; HAT: hydrogen atom transfer; MIC: minimum inhibitory concentration; ORAC: oxygen radical

26 absorbance capacity assay; QE: quercetin equivalents; SET: single electron transfer; SL1: stem and leaf extract from

27 Mora; SL2: stem and leaf extract from Puerto Jiménez; TE: Trolox equivalents; TFC: total flavonoid content; TPC:

28 total phenolic content.

29

30 ABSTRACT

31 Context: *Witheringia solanacea* has traditionally been used in Latin American medicine for its anti-inflammatory and antimicrobial
32 properties, as well as for general pain management. However, few pharmacological studies have been conducted to validate these
33 traditional uses.

34 Aims: To determine the chemical composition and evaluate selected pharmacological activities of *W. solanacea* extracts using
35 various experimental models.

36 Methods: Hydroalcoholic extracts from fruit and aerial parts of *W. solanacea* were analyzed by high-performance thin layer
37 chromatography to detect secondary metabolites. Qualitative phytochemical screening and quantification of total phenolic and
38 flavonoid contents were performed. The antioxidant and antibacterial activities of the extracts were evaluated *in vitro*.
39 Additionally, acute oral toxicity, analgesic, and anti-inflammatory activities of the aerial-part extract were assessed in rats.

40 Results: Phytochemical analysis confirmed the presence of phenolics, flavonoids, coumarins, terpenoids, triterpenes, steroids, and
41 alkaloids. Fruit extracts exhibited higher antioxidant activity than aerial-part extracts. The extracts showed only limited
42 antibacterial activity, with effects observed only against *E. faecalis* (MIC \approx 5 mg/mL). The aerial-part extract was classified as non-
43 toxic (LD₅₀ > 2000 mg/kg). *In vivo*, this extract produced significant analgesic effects in the tail-flick model and significantly
44 reduced carrageenan-induced paw edema and leukocyte infiltration, with effects comparable to those of indomethacin.

45 Conclusions: *W. solanacea* aerial part extract exhibits analgesic and anti-inflammatory properties that support its traditional use
46 for pain and inflammation, although only limited antibacterial activity was observed.

47

48 Keywords: anti-inflammatory; antimicrobial; antinociceptive; antioxidant; oral toxicity; *Witheringia solanacea*.

49

50 RESUMEN

51 Contexto: La planta *Witheringia solanacea* ha sido utilizada tradicionalmente en la medicina latinoamericana por sus propiedades
52 antiinflamatorias y antimicrobianas, así como para el tratamiento del dolor en general. Sin embargo, pocos estudios
53 farmacológicos han validado estos usos tradicionales.

54 Objetivos: Determinar la composición química y evaluar algunas actividades farmacológicas de los extractos de *W. solanacea*
55 mediante diversos modelos experimentales.

56 Métodos: Se analizaron extractos hidroalcohólicos de frutos y partes aéreas de *W. solanacea* mediante cromatografía de capa fina
57 de alta resolución para detectar metabolitos secundarios. Además, se realizaron pruebas fitoquímicas cualitativas y determinación
58 del contenido de compuestos fenólicos y flavonoides totales. Los extractos fueron evaluados para determinar su actividad
59 antioxidante y antibacteriana *in vitro*. También se evaluó la toxicidad oral aguda y las actividades analgésicas y antiinflamatorias
60 del extracto de partes aéreas en ratas.

61 Resultados: El análisis fitoquímico confirmó la presencia de compuestos fenólicos, flavonoides, cumarinas, terpenoides,
62 triterpenos, esteroides y alcaloides. Los extractos de frutos mostraron una mayor actividad antioxidante que los extractos de
63 partes aéreas. Por otro lado, los extractos presentaron una débil actividad antibacteriana, observándose efectos únicamente contra

64 *E. faecalis* (CMI \approx 5 mg/mL). El extracto de partes aéreas se clasificó como no tóxico ($DL_{50} > 2000$ mg/kg). *In vivo*, este extracto
65 produjo efectos analgésicos significativos en el modelo de retiro de la cola y redujo significativamente el edema plantar inducido
66 por carragenina y la infiltración leucocitaria, con efectos comparables a los de la indometacina.

67 Conclusiones: El extracto de partes aéreas de *W. solanacea* presenta propiedades analgésicas y antiinflamatorias que respaldan su
68 uso tradicional para el tratamiento del dolor y la inflamación; sin embargo, se observó únicamente una actividad antibacteriana
69 limitada.

70

71 Palabras claves: antiinflamatorio; antimicrobiano; antinociceptivo; antioxidante; toxicidad oral; *Witheringia solanacea*

72 INTRODUCTION

73 *Witheringia solanacea* L'Hér is a small shrub (1-4 m high) that belongs to the Solanaceae
74 family. This species is widely distributed from southern Mexico to Bolivia in South America,
75 through Central America and the Caribbean islands. The plant is typically found between 0
76 and 2000 m above sea level (Pequeno et al., 2017).

77 *W. solanacea* has several medicinal ethnobotanical applications in Mesoamerica and South
78 America. For example, in Mexico and Nicaragua, this plant is used to treat skin illnesses such
79 as acne (Jacobo-Herrera et al., 2006; Coe, 2008). In Costa Rica, *W. solanacea* is used to treat
80 infections; the fruit is eaten to alleviate headaches and stomachaches, and the roots are used
81 to treat diabetes (García et al., 2006). In Panama, the whole plant and fruit are used for general
82 body pain, skin diseases, hypertension, and as an anthelmintic (Gupta et al., 1993; Caballero-
83 George et al., 2001). In Ecuador, the plant is widely used by several indigenous tribes; infusions
84 and the juice from the leaves and fruit are employed to treat headaches, inflammation, skin
85 infections, stomachaches, diarrhea, bronchitis and tuberculosis (Ballesteros et al., 2016).

86 Despite the extensive use of this plant in traditional Latin American medicine, few
87 pharmacological studies have confirmed the traditional use of *W. solanacea*. Some studies have
88 investigated the hypoglycemic activity (Herrera et al., 2011; Pequeno et al., 2021) and the
89 activity against malaria and leishmaniasis (Chinchilla et al., 2012; Chinchilla-Carmona et al.,
90 2014) of different extracts and parts of the plant.

91 Moreover, the phytochemistry of *W. solanacea* is not well known, but it has been related to
92 *Witheringia coccoloboides*, from which seven physalins have been isolated. Physalins are
93 steroidal lactones commonly present in the Solanaceae family and have a variety of biological
94 activities, such as antitumor, antibacterial, and anti-inflammatory properties (Wu et al., 2021;
95 Meira et al., 2022). Physalins B, D, and F have been isolated from the leaves of *W. solanacea*.

96 Physalins B and F have demonstrated anti-inflammatory effects in *in vitro* models using cell
97 cultures (Jacobo-Herrera et al., 2006).

98 To date, no studies have assessed the anti-inflammatory and analgesic activities of *W.*
99 *solanacea* in animal models, which could provide additional biologically relevant evidence
100 supporting the ethnobotanical applications of this plant. Furthermore, to the best of our
101 knowledge, no previous information has been reported regarding the evaluation of the
102 antibacterial effect of *W. solanacea* extracts, despite its traditional use for treating infections.
103 Given the limited pharmacological data available on *W. solanacea*, this study evaluated its
104 antimicrobial, anti-inflammatory, and analgesic activities using hydroalcoholic extracts of
105 fruit and aerial parts from two regions of Costa Rica. Acute oral toxicity, antioxidant capacity,
106 and phytochemical profiles were also determined.

107 MATERIAL AND METHODS

108 Collection of plant material

109 Aerial parts of *W. solanacea* were collected in February 2021 in two different locations of
110 Costa Rica: Puerto Jiménez, Puntarenas province (South Pacific Region) (8°33'14'' N,
111 83°23'56'' W) and Mora, San José province (Central Region) (9°54' 52.9'' N, 84°16'50.6'' W).
112 Taxonomic identification was performed by an expert botanist from the Nacional University
113 of Costa Rica. A voucher specimen of the species was deposited in the "Juvenal Valerio
114 Rodríguez" Herbarium (Nacional University of Costa Rica) under the acquisition numbers
115 JVR5362 and JVR5363, respectively.

116 Preparation of extracts

117 Combined stems and leaves of *W. solanacea* were shade-dried and ground to a particle size
118 of 2 mm using a blade mill (Wiley, United States). Ripe fruits were frozen at -80 °C and freeze-
119 dried using a LABCONCO Freezone 6 system (United States). The dried fruit was milled with

120 a food processor and sieved to a maximum particle size of 2 mm. Each plant material was
121 macerated separately in a 1:10 ratio with 80%(v/v) ethanol for two weeks. The extract was
122 decanted, and the plant residue was subjected to a second one-week maceration under the
123 same conditions. The resulting extract was decanted and combined with the first extract. The
124 pooled extract was filtered through a 0.45 μm PVDF membrane and ethanol was removed by
125 evaporation at 40 °C (Büchi R-100, Switzerland). The remaining aqueous phase was freeze-
126 dried to obtain the dried extracts. Four extracts were obtained, corresponding to: fruit from
127 Mora (F1), fruit from Puerto Jiménez (F2), stems and leaves from Mora (SL1), and stems and
128 leaves from Puerto Jiménez (SL2). Extraction yields were calculated, and the extracts were
129 stored at -20 °C for further analyses.

130 **Chemical characterization of the extracts**

131 Extracts solutions (10 mg/mL) were prepared in a 1:1 methanol-water mixture, and 25 μL
132 were applied onto HPTLC-grade silica gel 60 F254 plates (20 x 10 cm; Millipore, Germany).
133 Samples were sprayed as 8 mm x 1 mm bands using the ATS4 autosampler (CAMAG,
134 Switzerland) at 150 nL/s, with nitrogen as the propellant gas. The first band was positioned
135 20 mm from the left edge of the plate, and the solvent front was set at 80 mm from the bottom.
136 After application, the plates were dried for 30 seconds using the ADC2 automatic developing
137 chamber (CAMAG, Switzerland). The chamber was then saturated with the mobile phase.
138 Following saturation, the plates were developed and dried for 5 minutes. Chromatographic
139 development was conducted at room temperature (24 ± 3 °C) and relative humidity (51 ± 3 %).
140 Chromatograms were visualized under visible light or UV light (254 or 366 nm) using a TLC
141 visualizer (CAMAG, Switzerland).

142 *Conditions for the detection of phenolic compounds by HPTLC*

143 For the detection of highly polar phenolic compounds (e.g. glycosidic phenolics), a single
144 development system was employed using a mobile phase composed of butan-2-ol: *n*-butanol,

145 ethyl acetate, and formic acid (60:40:15:10). The development chamber was saturated for 20
146 minutes prior to use. For low-polarity phenolic compounds (e.g. non-glycosidic phenolics), a
147 two-step development system was applied. Plates were first developed with a mobile phase
148 of toluene, ethyl acetate, and formic acid (60:45:3), followed by a second elution using toluene,
149 ethyl acetate, *n*-hexane, and formic acid (60:30:10:3). The chamber was saturated for 10 minutes
150 before each elution step, and plates were dried in the ADC2 development chamber prior to
151 the second development. After development, plates were derivatized using potassium
152 ferricyanide and ferric chloride reagents (detection of phenolics), aluminum chloride reagent
153 (detection of flavonoids) or potassium hydroxide solution (detection of coumarins, flavonoids,
154 and quinones). All reagents were prepared and applied according to Lock de Ugaz (1994).

155 *Conditions for the detection of terpenoids by HPTLC*

156 Terpenoids were detected using a mobile phase of chloroform, methanol, and water
157 (100:40:5) after 20 minutes of chamber saturation. Following development, plates were
158 derivatized with either anisaldehyde/sulfuric acid or Liebermann-Burchard reagent, both
159 prepared and applied according to Lock de Ugaz (1994).

160 *Conditions for the detection of alkaloids by HPTLC*

161 Alkaloids were detected using a mobile phase of chloroform, methanol, and ammonium
162 hydroxide (47.5:47.5:5) after 20 minutes of chamber saturation. Following development, plates
163 were derivatized with Dragendorff's reagent, as described by Lock de Ugaz (1994).

164 *Additional qualitative tests*

165 Additionally, the extracts underwent preliminary phytochemical screening to identify
166 secondary metabolite groups, including carbohydrates, reducing sugars, amino acids and
167 peptides, saponins, tannins, and cardiac glycosides, following standard protocols (Lock de
168 Ugaz, 1994; Tiwari et al., 2011).

169 **Determination of Total Phenolic Content (TPC)**

170 TPC of the extracts were determined in triplicate using the 96-well Folin-Ciocalteu method
171 described by Bobo-García et al. (2015). Results were expressed as the mean concentration of
172 gallic acid equivalents (GAE) (mg GAE/g dry weight (DW)) \pm standard error of the mean
173 (SEM).

174 **Determination of Total Flavonoid Content (TFC)**

175 TFC of extracts was measured in triplicate using a modified aluminum chloride method
176 based on Magalhães et al. (2012). Quercetin was used as the standard at a concentration range
177 of 20–60 $\mu\text{g}/\text{mL}$. TFC values were expressed as mean quercetin equivalents (QE) (mg QE/g
178 DW) \pm SEM.

179 **Evaluation of antioxidant activity**

180 *Oxygen Radical Absorbance Capacity (ORAC) assay*

181 ORAC values were determined following the method of Kenny et al. (2015), with minor
182 modifications. Fluorescence decay curves of standard and samples were recorded over 1 hour.
183 A Trolox calibration curve was constructed within a linearity range of 20–60 μM . Each sample
184 was analyzed in triplicate, and antioxidant capacity was expressed as mean Trolox equivalents
185 (TE) ($\mu\text{mol TE}/\text{g DW}$) \pm SEM.

186 *Ferric Reducing Antioxidant Power (FRAP) assay*

187 FRAP values were measured using a microplate-adapted version of the method described
188 by Işıl et al. (2010). Trolox standards (20–100 μM) were prepared in methanol. Extract
189 concentrations were adjusted to fall within the linear range of the calibration curve. Aliquots
190 of 20 μL of Trolox or extract solutions were dispensed into microplate wells, followed by the
191 addition of 130 μL of 30 mM HCl, 25 μL of 1.2% (w/v) potassium ferricyanide, and 25 μL of

192 0.1% (w/v) iron (III) chloride hexahydrate. Methanol was used as the blank for the standard
193 instead of Trolox, while distilled water replaced potassium ferricyanide in the extract blanks
194 to correct for intrinsic absorbance. Plates were incubated at room temperature, and the
195 absorbance was measured at 700 nm using a Synergy HT microplate reader (BioTek
196 Instruments, USA). Each assay was performed in triplicate, and results were reported as mean
197 TE ($\mu\text{mol TE/g DW}$) \pm SEM.

198 *2,2-Diphenyl-1-picrylhydrazyl (DPPH) radical scavenging activity assay*

199 The concentration of extract required to reduce 50% of DPPH radicals (IC_{50}) was
200 determined using a microplate assay method adapted from Kenny et al. (2015). The IC_{50} values
201 were obtained by interpolation from dose-response curves fitted with the Hill equation. Each
202 determination was conducted in triplicate, and antioxidant activity was reported as mean IC_{50}
203 ($\mu\text{g/mL}$) \pm SEM.

204 *Ferrous Iron Chelating Activity (FICA) assay*

205 FICA was assessed following the procedure described by Santos et al. (2017), with minor
206 modifications. A 0.3 mM iron (II) chloride solution was used as iron (II) source, and the EDTA
207 standard curve ranged from 25-100 μM . Each assay was performed in triplicate, and results
208 were expressed as mean EDTA equivalents (EDTAE) ($\mu\text{mol EDTAE/g DW}$) \pm SEM.

209 **Evaluation of antibacterial activity**

210 *Staphylococcus aureus* (ATCC 6538), *Staphylococcus epidermidis* (ATCC 12228), *Enterococcus*
211 *faecalis* (ATCC 29212), *Pseudomonas aeruginosa* (ATCC 15442), *Escherichia coli* (ATCC BAA-
212 2452), *Klebsiella pneumoniae* (ATCC 10031), and *Salmonella enterica* subsp. *enterica* serovar
213 Typhimurium (known as *S. typhimurium*) (ATCC 14028) were employed as test
214 microorganisms. The minimum inhibitory concentration (MIC) of the extracts was determined
215 using the broth microdilution method, following the guidelines established by the European

216 Committee for Antimicrobial Susceptibility Testing (EUCAST, 2003) of the European Society
217 of Clinical Microbiology and Infectious Diseases (ESCMID). Extracts were tested at a
218 maximum concentration of 10 mg/mL. Ciprofloxacin hydrochloride was used as the positive
219 control for *E. coli* and *E. faecalis*, while ceftriaxone disodium salt was used for the remaining
220 strains. Dimethyl sulfoxide (DMSO) was employed as the solvent for the extracts, at a final
221 concentration not exceeding 1% (v/v) in the culture broth. For antibiotic controls, the culture
222 broth was used without any added solvent.

223 **Experimental animals**

224 Sprague–Dawley rats (11-12 weeks old) were obtained from the Biological Testing
225 Laboratory (LEBi), University of Costa Rica. All experimental protocols were approved by the
226 Institutional Committee for the Care and Use of Laboratory Animals (CICUA 038-2020) and
227 complied with the International Guiding Principles for Biomedical Research Involving
228 Animals (CIOMS). Animals were maintained under standard conditions (22 ± 2 °C, light/dark
229 cycles of 12 h) and *ad libitum* access to food and water.

230 Due to limited fruit availability, only the stem and leaf extract (SL2) was used for *in vivo*
231 tests. SL2 was selected over SL1 because of its higher total phenolic content and antioxidant
232 activity, suggesting a greater presence of bioactive compounds.

233 **Acute oral toxicity test**

234 The acute oral toxicity of SL2 was evaluated according to OECD guideline 423. A single
235 oral dose of 2000 mg/kg (dissolved in distilled water) was administered to six female Sprague-
236 Dawley rats (11 weeks old, 260 ± 15 g) fasted overnight. A control group received distilled
237 water. Animals were observed at 30, 60, 120, 180, and 240 minutes after treatment and daily
238 for 14 days. Clinical signs (e.g. tremors, convulsions, dehydration, salivation, diarrhea,
239 lethargy), as well as respiratory, circulatory, autonomic, and central nervous system function,

240 were monitored. Body weight was recorded every two days. At the end of the observation
241 period, animals were euthanized (150 mg/kg i.p. pentobarbital overdose), and necropsies
242 were performed to assess macroscopic changes in target organs.

243 **Evaluation of antinociceptive activity by the tail flick test**

244 Antinociceptive effects were assessed using the tail flick test described by D'Amour and
245 Smith (1941), with a Tail Flick Unit-Thermal Stimulation device (Ugo Basile, model 7360). Male
246 Sprague–Dawley rats (12 weeks old, 350 ± 20 g) were randomized into four groups ($n = 8$) and
247 treated i.p. with SL2 extract dissolved in saline solution (500 or 1000 mg/kg), morphine (5
248 mg/kg) as positive control, or saline solution (1 mL) as negative control. Tail withdrawal
249 latency was measured 10 minutes before (pre-treatment latency), and at 30, 60, 90, and 120
250 minutes after administration of treatments (post-treatment latency). All measurements were
251 performed at the midpoint of the distal third of the tail. A 20 s cut-off time was applied to
252 prevent tissue damage. Results were expressed as percentage of antinociception (A%)
253 according to the following formula: $A\% = (post-treatment\ latency - pre-treatment\ latency) / (cut-$
254 $off\ time - pre-treatment\ latency) \times 100$.

255 **Evaluation of anti-inflammatory activity by the carrageenan-induced paw edema model**

256 The anti-inflammatory effect was assessed according to the method described by Winter et
257 al. (1962), with minor modifications. Male Sprague–Dawley rats (11 weeks old, 300 ± 20 g)
258 were randomized into four groups ($n = 8$) and treated i.p. with SL2 extract dissolved in saline
259 solution (250 or 500 mg/kg), indomethacin (50 mg/kg) as positive control, or saline (1 mL) as
260 negative control. After one hour, 0.1 mL 1% (w/v) of carrageenan was injected subplantarily
261 into the right hind paw, and 0.1 mL of saline into the left paw. Paw thickness was measured
262 in duplicate at 1, 2, 4, 6, and 24 hours using a digital caliper (Kroeplin, model C330). Results
263 were expressed as percentage of edema (E%) according to the following formula: $E\% = (right$
264 $paw\ size - left\ paw\ size) / (left\ paw\ size) \times 100$.

265 *Histology of paw tissue*

266 At the end of the anti-inflammatory evaluation, animals were euthanized by decapitation.
267 Subplantar skin samples were fixed in 10% formalin-PBS for 48 h, processed, embedded in
268 paraffin, sectioned (5 μ m), and stained with hematoxylin–eosin. Histopathological evaluation
269 focused on tissue congestion and leukocyte infiltration.

270 **Statistical analysis**

271 Results were expressed as means \pm SEM. Data from antioxidant activity assays were
272 analyzed by one-way ANOVA followed by Tukey's *post hoc* tests and Pearson's correlation. *In*
273 *vivo* results were analyzed using two-way repeated measures ANOVA followed by Dunnett's
274 multiple comparisons test. A p value < 0.05 was considered statistically significant. Analyses
275 were performed using the GraphPad Prism® version 8.

276 **RESULTS**

277 **Chemical characterization of the extracts**

278 Data from the detection of different groups of metabolites in the ethanolic extracts obtained
279 from *W. solanacea* are summarized in Table 1. HPTLC chromatograms are shown in Figs. 1 to
280 4. Fruit extracts contained a more diverse array of phenolic compounds compared to extracts
281 from stems and leaves (Fig. 1A). Moreover, most of the phenolics present in the extracts were
282 highly polar. The flavonoids present in F1 and F2 consisted of a mixture of polar and non-
283 polar compounds, with F1 containing the greatest number of such compounds (Fig. 1B and
284 Fig. 2B). Coumarins were only detected in SL1 and SL2 under low-polarity HPTLC
285 development conditions; however, under high-polarity elution conditions, coumarins were
286 also found in F2 but not in F1 (Fig. 1C and Fig. 2C).


287

288 **Table 1.** Results of qualitative tests for the detection of metabolite groups in *W. solanacea* extracts.

Detected metabolites	Extract			
	F1	F2	SL1	SL2
Metabolites detected by HPTLC				
Phenolics	+	+	+	+
Flavonoids	+	+	+	+
Quinones	-	-	-	-
Coumarins	-	+	+	+
Terpenoids	+	+	+	+
Triterpenes and Steroids	+	+	+	+
Alkaloids	+	+	-	-
Metabolites detected by qualitative phytochemical screening				
Carbohydrates (Molisch test)	+	+	+	+
Carbohydrates (Benedict test)	+	+	+	+
Amino acids and peptides (Ninhydrin test)	+	+	+	+
Amino acids and peptides (Biuret test)	+	+	+	+
Saponins (Foam test)	-	-	-	-
Tannins (Protein precipitation test)	-	-	-	-

Cardiac glycosides (Kedde test)	-	-	-	-
Cardiac glycosides (Keller-Killiani test)	-	-	-	-
+: Positive result; -: Negative result. F1: Fruit extract from Mora; F2: Fruit extract from Puerto Jiménez; SL1: Stem and leaf extract from Mora; SL2: Stem and leaf extract from Puerto Jiménez.				

289



Dr: observation after derivatization; Dv: observation after development; F1: fruit extract from Mora; F2: fruit extract from Puerto Jiménez; SL1: stem and leaf extract from Mora; SL2: stem and leaf extract from Puerto Jiménez; UV: chromatogram under UV light (366 nm); Vis: chromatogram observed under visible light. Major positive changes are highlighted with yellow or black boxes.

290




Figure 2. Chromatograms showing the detection of non-polar phenolic compounds in *W. solanacea* extracts. **A)** General phenolics (derivatization with potassium ferricyanide and ferric chloride reagent). **B)** Flavonoids (derivatization with aluminum chloride reagent). **C)** Coumarins, flavonoids, and quinones (derivatization with potassium hydroxide reagent).

Dr: observation after derivatization; Dv: observation after development; F1: fruit extract from Mora; F2: fruit extract from Puerto Jiménez; SL1: stem and leaf extract from Mora; SL2: stem and leaf extract from Puerto Jiménez; UV: chromatogram under UV

Figure 3. Chromatograms showing the detection of terpenoids in *W. solanacea* extracts. **A)** General terpenoids (derivatization with anisaldehyde/sulfuric acid reagent). **B)** Steroids and triterpenoids (derivatization Liebermann-Burchard reagent).
 Dr: observation after derivatization; Dv: observation after development; F1: fruit extract from Mora; F2: fruit extract from Puerto Jiménez; SL1: stem and leaf extract from Mora; SL2: stem and leaf extract from Puerto Jiménez; UV: chromatogram under UV light (366 nm); Vis: chromatogram observed under visible light. Major positive changes are highlighted with yellow or black boxes.

297




Figure 4. Chromatograms showing the detection of alkaloids in *W. solanacea* extracts by derivatization with Dragendorff reagent.
 Dr: observation after derivatization; Dv: observation after development; F1: fruit extract from Mora; F2: fruit extract from Puerto Jiménez; SL1: stem and leaf extract from Mora; SL2: stem and leaf extract from Puerto Jiménez; Vis: chromatogram observed under visible light. Major positive changes are highlighted with black boxes.

298 **Determination of TPC, TFC and antioxidant activity**

299 The results of the TPC and TFC assays are presented in Fig. 5A and Fig. 5B. Fruit extracts
 300 showed higher levels of TPC and TFC compared to stem and leaf extracts. F1 had the highest
 301 TPC value (59.1 ± 0.9 mg GAE/g), whereas F2 showed the highest TFC level (127.7 ± 5 mg
 302 QE/g).





Figure 5. Determination of TPC, TFC, and antioxidant activity of *W. solanacea* extracts. **A)** TPC values. **B)** TFC values. **C)** ORAC values. **D)** FRAP values. **E)** IC₅₀ DPPH values. **F)** FICA values.

Different capital letters above the bars indicate significant differences ($p < 0.05$). Results are expressed as mean \pm SEM ($n = 3$). DPPH: 2,2-diphenyl-1-picrylhydrazyl assay; DW: dry weight; EDTAE: ethylenediaminetetraacetic acid equivalents; F1: fruit extract from Mora; F2: fruit extract from Puerto Jiménez; FICA: ferrous iron chelating activity assay; FRAP: ferric reducing antioxidant power assay; GAE: gallic acid equivalents; ORAC: oxygen radical absorbance capacity assay; QE: quercetin equivalents; SL1: stem and leaf extract from Mora; SL2: stem and leaf extract from Puerto Jiménez; TE: Trolox equivalents; TFC: total flavonoid content; TPC: total phenolic content.

303 Regarding the antioxidant activity assays, fruit extracts exhibited the strongest antioxidant
 304 activity in ORAC, FRAP, and DPPH assays (Fig. 5C, Fig. 5D, and Fig. 5E). F1 was the most
 305 potent extract in these assays, with ORAC, FRAP, and DPPH IC₅₀ values of 1796 ± 63 μmol
 306 TE/g , 472.7 ± 5.4 $\mu\text{mol TE/g}$, and 51.6 ± 2.5 $\mu\text{g/mL}$, respectively. In the FICA assay (Fig. 5F),
 307 F2 and SL2 were the most active, with FICA values of 104.6 ± 0.5 $\mu\text{mol EDTAE/g}$ and $103.1 \pm$
 308 0.7 $\mu\text{mol EDTAE/g}$, respectively.

309 On the other hand, Fig. 6 indicates a significant correlation between TPC and TFC values
 310 and the antioxidant activities evaluated by ORAC, DPPH and FRAP assays. However, the
 311 results from the FICA assay did not show a correlation with either TPC or TFC.



312 **Determination of antibacterial activity**

313 Table 2 summarizes the results from the broth microdilution assay. SL2 was the only active
314 extract, with a MIC value of 5 mg/mL against *E. faecalis*, which is classified as exhibiting mild
315 antibacterial activity based on the criteria reported by Bussmann et al. (2010).

316 **Table 2.** Antibacterial activity of *W. solanacea* extracts against selected bacterial strains.

Bacteria	Minimum Inhibitory Concentration				
	F1 (mg/mL)	F2 (mg/mL)	SL1 (mg/mL)	SL2 (mg/mL)	Control* (μ g/mL)
<i>S. aureus</i> (ATCC 6538)	>5	>5	>5	>5	4
<i>S. epidermidis</i> (ATCC 12228)	>5	>5	>5	>5	2
<i>E. faecalis</i> (ATCC 29212)	>5	>5	>5	5	0.5
<i>P. aeruginosa</i> (ATCC 15442)	>5	>5	>5	>5	32
<i>E. coli</i> (ATCC BAA-2452)	>5	>5	>5	>5	0.03
<i>K. pneumoniae</i> (ATCC 10031)	>5	>5	>5	>5	0.03
<i>S. typhimurium</i> (ATCC 14028)	>5	>5	>5	>5	0.06
*Control: ciprofloxacin chloride for <i>E. coli</i> and <i>E. faecalis</i> , or ceftriaxone disodium salt for other bacteria. F1: fruit extract from Mora; F2: fruit extract from Puerto Jiménez; SL1: stem and leaf extract from Mora; SL2: stem and leaf extract from Puerto Jiménez.					

318 **Acute toxicity test**

319 The acute toxicity test revealed that oral administration of SL2 extract at a single dose of
320 2000 mg/kg did not cause mortality in the rats during the 14 days of the assay. Since the
321 median lethal dose (LD₅₀) is greater than 2000 mg/kg, this extract is classified as non-toxic
322 according to OECD guideline 423. Moreover, the extract did not cause significant changes in
323 behavior, general appearance, or any signs of toxicity during 14 days following
324 administration. Body weight gain in both control and treated groups was similar. Necropsy
325 conducted 14 days post-administration revealed no significant macroscopic alterations in the
326 target organs.

327 **Antinociceptive activity**

328 The results of the antinociceptive activity of the SL2 extract are presented in Fig. 7. The tail-
329 flick test showed a significant ($p = 0.0334$) increase in baseline latency time (i.e., the time
330 required to withdraw the tail) 30 min after the treatment with 1000 mg/kg of SL2 extract
331 compared to the control group. No significant effect was observed at later time points or with
332 the 500 mg/kg dose. As expected, morphine (5 mg/kg) caused a significant increase in latency
333 time at 30, 60, and 90 minutes post-treatment compared to the control ($p = 0.0005$, $p = 0.0009$,
334 and $p = 0.0119$, respectively). Administration of the vehicle did not significantly affect the
335 nociceptive threshold.




Figure 7. Antinociceptive effect of the stem and leaf extract from Puerto Jiménez (SL2) in the tail flick test in rats.

Results are presented as the mean \pm SEM of the percentage of antinociception ($n = 8$). Statistical significance was determined by two-way repeated measures ANOVA followed by Dunnett's multiple comparisons test. * $p < 0.05$, *** $p < 0.001$ compared to control (saline solution).

336 Anti-inflammatory activity

337 The results of the anti-inflammatory activity of the SL2 extract are shown in Fig. 8. Injection
 338 of carrageenan into the hind paw tissue of rats pretreated with vehicle (control group) caused
 339 a progressive increase in paw edema that persisted for 24 hours, with a maximum effect at 4
 340 and 6 hours. Pretreatment with 500 mg/kg of SL2 extract significantly reduced the edema
 341 induced by carrageenan at 2 and 4 hours post-injection compared to the control group ($p =$
 342 0.0209 and $p = 0.0043$, respectively). No significant reduction was observed at 1, 6 or 24 hours,
 343 although a trend toward decreased edema was noted across all time points, similar in
 344 magnitude to the indomethacin group. Pretreatment with 250 mg/kg of SL2 extract
 345 significantly ($p = 0.0222$) reduced edema only at 4 hours post-injection. No significant
 346 reduction in inflammation was observed at 1, 2, 6, or 24 hours. Indomethacin (50 mg/kg)

347 produced a significant reduction in paw edema at 2 and 4 hours post-injection as compared to
 348 the control group ($p = 0.0229$ and $p = 0.0143$, respectively).





Figure 8. Anti-inflammatory effect of the stem and leaf extract from Puerto Jiménez (SL2) extract in carrageenan-induced paw edema in rats.

Results are presented as the mean \pm SEM of the percentage of edema (right hind paw) relative to non-inflamed control (left hind paw) ($n = 8$). Statistical significance was determined by two-way repeated measures ANOVA followed by Dunnett's multiple comparison test. * $p < 0.05$ compared to control (saline solution).

349 The histological biopsies of the rat paw 24 hours after carrageenan injection are presented
 350 in Fig. 9. Paw tissue from the control group pretreated with vehicle (Fig. 9A) showed typical
 351 signs of acute inflammation, including leukocyte infiltration and congestion, compared to
 352 normal paw tissue (Fig. 9B). Pretreatment with indomethacin decreased paw swelling and
 353 leukocyte infiltration (Fig. 9E). Pretreatment with 500 mg/kg of SL2 extract similarly reduced
 354 swelling and leukocyte infiltration to a comparable extent (Fig. 9C). Paw tissue from animals
 355 pretreated with 250 mg/kg of SL2 extract showed more leukocyte infiltration and congestion
 356 than the group treated with the higher dose (Fig. 9D).



357 DISCUSSION

358 In Latin American countries, *W. solanacea* has traditionally been used for various purposes,
 359 including as an anti-inflammatory and antimicrobial agent, and for general pain relief.
 360 Ethnobotanical reports describe the use of different parts of the plant – such as fruits, stems,
 361 and leaves - prepared using diverse methods (Gupta et al., 1993; Caballero-George et al., 2001;
 362 García et al., 2006; Jacobo-Herrera et al., 2006; Coe, 2008; Ballesteros et al., 2016). Given the

363 diversity in traditional preparations, ethanolic extracts of each plant material were prepared
364 for chemical characterization and biological evaluation.

365 The primary finding from chemical characterization was the variation among extracts from
366 different plant parts and collection sites. Phytochemical screening and HPTLC analysis
367 revealed the presence of phenolics, flavonoids, coumarins, terpenoids, alkaloids, triterpenes,
368 and steroids. Variation in phytochemical profiles between plant parts is typical in medicinal
369 plants (Ak et al., 2020). Furthermore, chemical differences related to collection sites have been
370 reported in other species (Camara et al., 2021). F1 and SL1 were collected in Costa Rica's
371 Central Valley (cooler, moderate rainfall), while F2 and SL2 were from the South Pacific
372 Region (hotter, more humid). Environmental factors such as altitude, temperature, solar
373 radiation, and precipitation are known to influence the metabolite profiles (Liu et al., 2016).
374 Genotypic variation may also contribute to the observed differences (Camara et al., 2021).
375 These aspects warrant further in-depth investigation.

376 The extracts were rich in triterpenoid and steroidal compounds, consistent with previous
377 reports of these metabolite groups in species of the *Witheringia* genus, including *W. solanacea*
378 (Pequeno et al., 2017). Previous studies have isolated physalins –steroidal lactones– from
379 this species (Jacobo-Herrera et al., 2006).

380 As expected for Solanaceae species, fruit extracts were positive for alkaloids. Several
381 alkaloids from this family exhibit anti-inflammatory activity (Xia et al., 2021). Thus, identifying
382 the alkaloids in *W. solanacea* fruit and evaluating their anti-inflammatory potential is a
383 promising research direction. Unfortunately, this analysis could not be conducted due to
384 limited fruit availability.

385 Consistent with qualitative assays, *in vitro* analyses revealed differences in TPC and TFC
386 values, and antioxidant activity among extracts from different regions, likely due to

387 environmental variation. Fruit extracts showed higher TPC and TFC values, and stronger
388 antioxidant activities compared to stem and leaf extracts. Similar differences in TPC, TFC, and
389 antioxidant activity among plant parts have been reported in related species, such as *Withania*
390 *somnifera* (Alam et al., 2012; Sahoo et al., 2024) and *Physalis peruviana* (Ertürk et al., 2017),
391 although their extracts exhibited lower values than those of *W. solanacea* in the present study.

392 The antioxidant capacity was evaluated using assays based on different chemical
393 mechanisms. Phenolic compounds and flavonoids are known to stabilize free radicals and to
394 chelate transition metals involved in Fenton and Haber-Weiss reactions (Perron and
395 Brumaghim, 2009). A positive correlation was observed between TPC/TFC and antioxidant
396 activities in the ORAC, DPPH, and FRAP assays. In contrast, no such correlation was found
397 with FICA results, possibly due to differences in compounds responsible for metal chelation.
398 This hypothesis is supported by the observed variations in phenolic composition among the
399 extracts.

400 Antibacterial activity was assessed due to traditional use of *W. solanacea* for treating
401 infections (García et al., 2006; Jacobo-Herrera et al., 2006). Only the stem and leaf extract of *W.*
402 *solanacea* from Puerto Jiménez showed mild activity against *E. faecalis*, a pathogen involved in
403 external and internal infections. Although limited, these findings are noteworthy due to the
404 lack of prior antibacterial studies, despite its traditional use.

405 *In vivo* studies were conducted only with the stem and leaf extract due to limited fruit
406 availability. SL2 was selected based on higher TPC and antioxidant activity than SL1,
407 suggesting greater concentration of active metabolites.

408 Toxicological evaluation is essential for medicinal plant research. Thus, the acute oral
409 toxicity of SL2 was assessed prior to its pharmacological evaluation. Results indicated no acute
410 toxicity at doses up to 2000 mg/kg. This is a relevant finding, given the lack of previous

411 toxicological studies for *W. solanacea* or related species. These results are consistent with
412 previous studies conducted with extracts from plants of the Solanaceae family, in which many
413 species have been shown to exhibit low acute oral toxicity in animal models at doses of up to
414 5000 mg/kg (Parra et al., 2001; Epoh et al., 2019; Moussaoui et al., 2020).

415 Pain is a common symptom associated with numerous medical conditions. In Latin
416 America, *W. solanacea* is traditionally used to treat headaches and general pain (Gupta et al.,
417 1993; Caballero-George et al., 2001; García et al., 2006); although no pharmacological studies
418 had been reported prior to this work. The tail flick test is a well-established method for
419 assessing analgesic properties, measuring the latency of the tail flick reflex following thermal
420 stimulation, which activates pain responses at spinal and/or supraspinal levels (Barrot, 2012).
421 Although the SL2 extract of *W. solanacea* produced an analgesic effect only during the first 30
422 minutes of the test, this finding is noteworthy considering its traditional use for pain relief and
423 the absence of previous pharmacological evidence.

424 The phenolic-rich profile of *W. solanacea* may explain its analgesic potential, as such
425 compounds possess antinociceptive activity (Sun and Shahrajabian, 2023). Additionally, some
426 physalins—compounds identified in *W. solanacea*—have been reported to possess analgesic
427 properties (Wu et al., 2021; Jacobo-Herrera et al., 2006). These components may contribute to
428 the observed analgesic effects of the plant. However, further studies should be conducted
429 using additional nociception and pain models to confirm this activity and to identify the
430 specific active metabolites involved.

431 The carrageenan-induced paw edema model, which mimics acute inflammation, was used
432 to assess anti-inflammatory activity. This model involves two phases: an early phase involving
433 the release of mediators such as histamine, serotonin, and bradykinin, and a later phase
434 characterized by increased cyclooxygenase (COX) and nitric oxide synthase activity, leading
435 to edema and leukocyte infiltration (McKim et al., 2016). The SL2 extract reduced edema at 2

436 and 4 hours and decreased leukocyte infiltration at 24 hours, similar to indomethacin,
437 suggesting inhibition of pro-inflammatory enzymes. These findings indicate a modulatory
438 effect on acute inflammation; however, further mechanistic studies are needed.

439 Previous research demonstrated that physalins B and F (but not D) from *W. solanacea*
440 modulate NF- κ B in cell models (Jacobo-Herrera et al., 2006). Other studies have confirmed the
441 anti-inflammatory effects of physalins through suppression of cytokines (Meira et al., 2022).
442 However, *in vivo* evidence of anti-inflammatory activity for *W. solanacea* was previously
443 lacking. The present findings provide novel *in vivo* confirmation that supports its traditional
444 medicinal use.

445 Finally, antioxidant polyphenols may contribute to the observed anti-inflammatory effects
446 (Roy et al., 2022). Phenolic acids and flavonoids have been shown to mitigate oxidative stress
447 in inflammation models, including carrageenan-induced paw edema, in which oxidative stress
448 is a key component (Albarakati, 2022). Thus, in addition to physalins, polyphenols are likely
449 contributors to the anti-inflammatory activity of *W. solanacea*. Future studies could include
450 fractionation of the active extract to isolate specific anti-inflammatory or analgesic
451 compounds, and assessment of their effects on inflammatory mediators (e.g. COX, cytokines)
452 to elucidate mechanisms.

453 CONCLUSION

454 Extracts from the aerial parts of *W. solanacea* demonstrated anti-inflammatory and
455 antinociceptive effects with no observed acute toxicity. These results support the traditional
456 use of the plant for treating inflammation and pain. In contrast, antibacterial activity was
457 weak. The observed anti-inflammatory and analgesic effects may be attributed to antioxidant
458 phenolics, flavonoids, and known physalins present in the extracts. *W. solanacea* therefore
459 represents a promising source of compounds for managing inflammation and pain.

460 CONFLICT OF INTEREST

461 The authors declare that they have no competing financial interests that could influence the results reported in
462 this paper.

463 ACKNOWLEDGMENT

464 The authors would like to thank Jorge Poveda and Minor Carranza from the “Juvenal Valerio Rodríguez”
465 Herbarium (Universidad Nacional, Costa Rica), and German Madrigal from the Pharmaceutical Research
466 Institute (INIFAR, for its acronym in Spanish), University of Costa Rica, for their help in the collection and
467 identification of the plant. The authors also thank the technical staff and students from the School of Pharmacy,
468 University of Costa Rica, and from the Pharmaceutical Research Institute, University of Costa Rica, for their help
469 in some parts of the experiments. This work was supported by the University of Costa Rica (grant number 817-
470 C1-096).

471 DECLARATION OF GENERATIVE AI IN THE WRITING PROCESS

472 During the preparation of this work, the authors used ChatGPT in order to check grammar, spelling, and clarity.
473 After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the
474 published article.

475 REFERENCES

- 476 Ak G, Zengin G, Sinan KI, Mahomoodally MF, Picot-Allain MCN, Cakir O, Bensari S, Yilmaz MA, Gallo M,
477 Montesano D (2020) A comparative bio-evaluation and chemical profiles of *Calendula officinalis* L. extracts
478 prepared via different extraction techniques. Appl Sci 10: 5920. <https://doi.org/10.3390/app10175920>.
- 479 Alam N, Hossain M, Mottalib MA, Sulaiman SA, Gan SH, Khalil MI (2012) Methanolic extracts of *Withania somnifera*
480 leaves, fruits and roots possess antioxidant properties and antibacterial activities. BMC Complement Altern
481 Med 7: 175. <https://doi.org/10.1186/1472-6882-12-175>.
- 482 Albarakati AJA (2022) Protocatechuic acid counteracts oxidative stress and inflammation in carrageenan-induced
483 paw edema in mice. Environ Sci Pollut Res Int 29: 56393-56402. <https://doi.org/10.1007/s11356-022-19688-9>.
- 484 Ballesteros JL, Bracco F, Cerna M, Vita Finzi P, Vidari G (2016) Ethnobotanical research at the Kutukú Scientific
485 Station, Morona-Santiago, Ecuador. Biomed Res Int 2016: 1-18. <https://doi.org/10.1155/2016/9105746>.
- 486 Barrot M (2012) Tests and models of nociception and pain in rodents. Neuroscience 211: 39-50.
487 <https://doi.org/10.1016/j.neuroscience.2011.12.041>.

- 488 Bobo-García G, Davidov-Pardo G, Arroqui C, Vírseda P, Marín-Arroyo MR, Navarro M (2015) Intra-laboratory
489 validation of microplate methods for total phenolic content and antioxidant activity on polyphenolic extracts,
490 and comparison with conventional spectrophotometric methods. *J Sci Food Agric* 95: 204-209.
491 <https://doi.org/10.1002/jsfa.6706>.
- 492 Bussmann RW, Malca-García G, Glenn A, Sharon D, Chait G, Díaz D, Pourmand K, Jonat B, Somogy S, Guardado
493 G, Aguirre C, Chan R, Meyer K, Kuhlman A, Townesmith A, Effio-Carbajal J, Frías-Fernández F, Benito M
494 (2010) Minimum inhibitory concentrations of medicinal plants used in Northern Peru as antibacterial
495 remedies. *J Ethnopharmacol* 132: 101-108. <https://doi.org/10.1016/j.jep.2010.07.048>.
- 496 Caballero-George C, Vanderheyden PML, Solís PN, Pieters L, Shahat AA, Gupta MP, Vauquelin G, Vlietinck AJ,
497 (2001) Biological screening of selected medicinal Panamanian plants by radioligand-binding techniques.
498 *Phytomedicine* 8: 59-70. <https://doi.org/10.1078/0944-7113-00011>.
- 499 Camara A, Haddad M, Traore MS, Chapeland-Leclerc F, Ruprich-Robert G, Fourasté I, Balde MA, Royo J, Parny
500 M, Batigne P, Salon M, Coste A, Balde AM, Aubouy A (2021) Variation in chemical composition and
501 antimalarial activities of two samples of *Terminalia albida* collected from separate sites in Guinea. *BMC*
502 *Complement Med Ther* 21: 64. <https://doi.org/10.1186/s12906-021-03231-3>.
- 503 Chinchilla M, Valerio I, Sánchez R, Mora V, Bagnarello V, Martínez L, González A, Vanegas JC, Apestegui Á (2012)
504 *In vitro* antimalarial activity of extracts of some plants from a biological reserve in Costa Rica. *Rev Biol Trop*
505 60: 881-891. <https://doi.org/10.15517/rbt.v60i2.4024>.
- 506 Chinchilla-Carmona M, Valerio-Campos I, Sánchez-Porras R, Bagnarello-Madrigal V, Martínez-Esquivel L,
507 González-Paniagua A, Alpízar JC, Cordero-Villalobos M, Rodríguez-Chaves D (2014) Anti-leishmanial
508 activity in plants from a biological reserve of Costa Rica. *Rev Biol Trop* 62: 1229-1240.
509 <https://doi.org/10.15517/rbt.v62i3.12377>.
- 510 Coe FG (2008) Ethnomedicine of the Rama of southeastern Nicaragua. *J Ethnobiol* 28: 1-38.
511 https://doi.org/10.2993/0278-0771_2008_28_1_eotros_2.0.c.
- 512 D'Amour FE, Smith DL (1941) A method for determining loss of pain sensation. *J Pharmacol Exp Ther* 72: 74-79.
- 513 De La Torre L, Alarcón D, Kvist LP, Salazar J (2008) Usos medicinales de las plantas. *Enciclopedia de las Plantas*
514 *Útiles del Ecuador*. Herbario QCA de la Escuela de Ciencias Biológicas de la Pontificia Universidad Católica
515 del Ecuador & Herbario AAU del Departamento de Ciencias Biológicas de la Universidad de Aarhus.

- 516 Epoh NJ, Matafack OL, Tadjoua HT, Tchouanguiep FM, Telefo P (2019) Evaluation of acute and sub-acute toxicity
517 of the aqueous extract from the fruit of *Solanum indicum* Linn. (Solanaceae) in rats. Eur J Med Plant 30: 1-16.
518 <https://doi.org/10.9734/ejmp/2019/v30i330179>.
- 519 Ertürk Ö, Çol ayvaz M, Can Z, Karaman Ü, Korkmaz K (2017) Antioxidant, antimicrobial activities and phenolic
520 and chemical contents of *Physalis peruviana* L. from Trabzon, Turkey. Indian J Pharm Educ Res 51: S213-16.
521 <https://doi.org/10.5530/ijper.51.3s.15>.
- 522 European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical
523 Microbiology and Infectious Diseases (ESCMID) (2003). Determination of minimum inhibitory concentrations
524 (MICs) of antibacterial agents by broth dilution. Clin Microbiol Infect 9: ix-xv.
525 <https://doi.org/10.1046/j.1469-0691.2003.00790.x>.
- 526 García M, Sánchez P, Poveda L, Otárola M (2006) Proyecto etnobotánico del Caribe Norte de Costa Rica. Estación
527 Biológica Cano Palma, Universidad Nacional de Costa Rica (UNA).
- 528 Gupta MP, Correa MD, Solís PN, Jones A, Galdames C, Guionneau-Sinclair F (1993) Medicinal plant inventory of
529 *Kuna Indians*: Part 1. J Ethnopharmacol 40: 77-109. [https://doi.org/10.1016/0378-8741\(93\)90054-9](https://doi.org/10.1016/0378-8741(93)90054-9).
- 530 Herrera C, García-Barrantes PM, Binns F, Vargas M, Poveda L, Badilla S (2011) Hypoglycemic and
531 antihyperglycemic effect of *Witheringia solanacea* in normal and alloxan-induced hyperglycemic rats. J
532 Ethnopharmacol 133: 907-910. <https://doi.org/10.1016/j.jep.2010.10.003>.
- 533 Işıl K, Güçlü K, Tor İ, Demirata B, Apak R (2010) Total antioxidant capacity assay using optimized
534 ferricyanide/prussian blue method. Food Anal Methods 3: 154-168. <https://doi.org/10.1007/s12161-009-9117-9>.
- 535
- 536 Jacobo-Herrera NJ, Bremner P, Márquez N, Gupta MP, Gibbons S, Muñoz E, Heinrich M (2006) Physalins from
537 *Witheringia solanacea* as modulators of the NF-κB cascade. J Nat Prod 69: 328-331.
538 <https://doi.org/10.1021/np050225t>.
- 539 Kenny O, Brunton NP, Smyth TJ (2015) *In vitro* protocols for measuring the antioxidant capacity of algal extracts.
540 In: Stengel DB, Connan S (eds.), Natural Products from Marine Algae. New York: Humana Press, pp 375-402.
541 https://doi.org/10.1007/978-1-4939-2684-8_24.

- 542 Liu W, Yin D, Li N, Hou X, Wang D, Li D, Liu J (2016) Influence of environmental factors on the active substance
543 production and antioxidant activity in *Potentilla fruticosa* L. and its quality assessment. *Sci Rep* 6: 28591.
544 <https://doi.org/10.1038/srep28591>.
- 545 Lock de Ugaz O (1994) Investigación fitoquímica: métodos en el estudio de productos naturales. Pontificia
546 Universidad Católica del Perú Fondo Editorial, Perú. <https://doi.org/10.18800/9788483909522>.
- 547 Magalhães LM, Almeida MIGS, Barreiros L, Reis S, Segundo MA (2012) Automatic aluminum chloride method for
548 routine estimation of total flavonoids in red wines and teas. *Food Anal Methods* 5: 530-539.
549 <https://doi.org/10.1007/s12161-011-9278-1>.
- 550 McKim JM, Baas H, Rice GP, Willoughby JA, Weiner ML, Blakemore W (2016) Effects of carrageenan on cell
551 permeability, cytotoxicity, and cytokine gene expression in human intestinal and hepatic cell lines. *Food*
552 *Chem Toxicol* 96: 1-10. <https://doi.org/10.1016/j.fct.2016.07.006>.
- 553 Meira CS, Soares JWC, dos Reis BPZC, Pacheco LV, Santos IP, Silva DKC, de Lacerda JC, Daltro SRT, Guimarães
554 ET, Soares MBP (2022) Therapeutic applications of physalins: powerful natural weapons. *Front Pharmacol* 13:
555 864714. <https://doi.org/10.3389/fphar.2022.864714>.
- 556 Min H, Ji-Xiang H, Hui-Xin H, Kan Z, Xiao-Ning W, Bao-Bing Z, Hong-Xiang L, Dong-Mei R, Tao S (2019)
557 Withanolides from the genus *Physalis*: a review on their phytochemical and pharmacological aspects. *J Pharm*
558 *Pharmacol* 72: 649-669. <https://doi.org/10.1111/jphp.13209>.
- 559 Moussaoui AEL, Bourhia MM, Jawhari FZ, Es-Safi I, Ali SS, Bari A, Mahmood HM, Bousta D, Bari A (2020) *Withania*
560 *frutescens*. L extract: phytochemical characterization and acute and repeated dose 28-day oral toxicity studies
561 in mice. *Biomed Res Int* 26: 2020. <https://doi.org/10.1155/2020/1976298>
- 562 OECD (2002) OECD guideline for testing of chemicals: 423. Acute oral toxicity, OECD Guidelines for the testing of
563 chemicals. OECD Publishing, Paris.
- 564 Parra AL, Yhebra RS, Sardiñas IG, Buela LI (2001) Comparative study of the assay of *Artemia salina* L. and the
565 estimate of the medium lethal dose (LD₅₀ value) in mice, to determine oral acute toxicity of plant extracts.
566 *Phytomedicine* 8: 395-400. <https://doi.org/10.1078/0944-7113-00044>
- 567 Pequeno A, Miranda Y, Rodríguez G, Valverde V, Álvarez L, Juvenal H, Rodríguez V, Da Silva T, Da V, Junior S
568 (2017) The genus *Witheringia*: A review of its traditional uses, phytochemistry and pharmacology. *Int J Herb*
569 *Med* 5: 11-15.

- 570 Pequeno AP, da Silva TMS, de Oliveira VVG, da Silva VA (2021) Hypoglycemic effect and histopathological
571 changes of the ethanolic extract of *Witheringia solanaceae* L'Hér fruits. J Morphol Sci 38: 305-308.
572 <https://doi.org/10.51929/jms.38.52.2021>.
- 573 Perron NR, Brumaghim JL (2009) A review of the antioxidant mechanisms of polyphenol compounds related to
574 iron binding. Cell Biochem Biophys 53: 75-100. <https://doi.org/10.1007/s12013-009-9043-x>.
- 575 Roy A, Das S, Chatterjee I, Roy S, Chakraborty R (2022) Anti-inflammatory effects of different dietary antioxidants.
576 In: Ekiert HM, Ramawat KG, Arora J (eds.). Plant Antioxidants and Health. Reference Series in
577 Phytochemistry. Springer, Cham. https://doi.org/doi.1007/978-3-030-78160-6_20.
- 578 Sahoo M R, Varrier RR, Sharma BSH, Rajendran A, Guru B (2024) Phytochemical profiling for leaf, stem, roots, and
579 seeds of *Withania somnifera* (L.) Dunal. J Rep Pharm Sci 12: e146161. <https://doi.org/10.5812/jrps.146161>.
- 580 Santos JS, Alvarenga VR, Granato D (2017) High-throughput assay comparison and standardization for metal
581 chelating capacity screening: A proposal and application. Food Chem 214: 515-522.
582 <https://doi.org/10.1016/j.foodchem.2016.07.091>.
- 583 Sun W, Shahrajabian MH (2023) Therapeutic potential of phenolic compounds in medicinal plants-natural health
584 products for human health. Molecules 28: 1845. <https://doi.org/10.3390/molecules28041845>.
- 585 Tiwari P, Kumar B, Mandeep K, Kaur G, Kaur H (2011) Phytochemical screening and extraction: A review. Int
586 Pharm Scientia 1: 98-101.
- 587 Winter CA, Risley EA, Nuss GW (1962) Carrageenin-induced edema in hind paw of the rat as an assay for
588 antiinflammatory drugs. Proc Soc Exp Biol Med 111: 544-547. <https://doi.org/10.3181/00379727-111-27849>.
- 589 Wu J, Zhao J, Zhang T, Gu Y, Khan IA, Zou Z, Xu Q (2021) Naturally occurring physalins from the genus *Physalis*:
590 A review. Phytochemistry 191: 112925. <https://doi.org/10.1016/j.phytochem.2021.112925>.
- 591 Xia W, Kolli AR, Koshihu K, Martin F, Kondylis A, Kuczaj A, Tan WT, Yeo YS, Tan G, Teng C, Woon K, Schneider
592 T, Talikka M, Phillips BW, Vanscheeuwijck P, Peitsch MC, Hoeng J (2021) *In vivo* profiling of a natural alkaloid,
593 anatabine, in rodents: pharmacokinetics and anti-inflammatory efficacy. J Nat Prod 84: 1012-1021.
594 <https://doi.org/10.1021/acs.jnatprod.0c01044>.

595 **Legends of figures**

596 **Figure 1.** Chromatograms showing the detection of polar phenolic compounds in *W. solanacea* extracts. **A)**
597 General phenolics (derivatization with potassium ferricyanide and ferric chloride reagent). **B)** Flavonoids
598 (derivatization with aluminum chloride reagent). **C)** Coumarins, flavonoids, and quinones (derivatization with
599 potassium hydroxide reagent).
600 Dr: observation after derivatization; Dv: observation after development; F1: fruit extract from Mora; F2: fruit extract from Puerto
601 Jiménez; SL1: stem and leaf extract from Mora; SL2: stem and leaf extract from Puerto Jiménez; UV: chromatogram under UV
602 light (366 nm); Vis: chromatogram observed under visible light. Major positive changes are highlighted with yellow or black
603 boxes.

604
605 **Figure 2.** Chromatograms showing the detection of non-polar phenolic compounds in *W. solanacea* extracts. **A)**
606 General phenolics (derivatization with potassium ferricyanide and ferric chloride reagent). **B)** Flavonoids
607 (derivatization with aluminum chloride reagent). **C)** Coumarins, flavonoids, and quinones (derivatization with
608 potassium hydroxide reagent).
609 Dr: observation after derivatization; Dv: observation after development; F1: fruit extract from Mora; F2: fruit extract from Puerto
610 Jiménez; SL1: stem and leaf extract from Mora; SL2: stem and leaf extract from Puerto Jiménez; UV: chromatogram under UV
611 light (366 nm); Vis: chromatogram observed under visible light. Major positive changes are highlighted with yellow or black
612 boxes.

613
614 **Figure 3.** Chromatograms showing the detection of terpenoids in *W. solanacea* extracts. **A)** General terpenoids
615 (derivatization with anisaldehyde/sulfuric acid reagent). **B)** Steroids and triterpenoids (derivatization
616 Liebermann-Burchard reagent).
617 Dr: observation after derivatization; Dv: observation after development; F1: fruit extract from Mora; F2: fruit extract from Puerto
618 Jiménez; SL1: stem and leaf extract from Mora; SL2: stem and leaf extract from Puerto Jiménez; UV: chromatogram under UV
619 light (366 nm); Vis: chromatogram observed under visible light. Major positive changes are highlighted with yellow or black
620 boxes.

621
622 **Figure 4.** Chromatograms showing the detection of alkaloids in *W. solanacea* extracts by derivatization with
623 Dragendorff reagent.
624 Dr: observation after derivatization; Dv: observation after development; F1: fruit extract from Mora; F2: fruit extract from Puerto
625 Jiménez; SL1: stem and leaf extract from Mora; SL2: stem and leaf extract from Puerto Jiménez; Vis: chromatogram observed
626 under visible light. Major positive changes are highlighted with black boxes.

627

628 **Figure 5.** Determination of TPC, TFC, and antioxidant activity of *W. solanacea* extracts. **A)** TPC values. **B)** TFC
 629 values. **C)** ORAC values. **D)** FRAP values. **E)** IC₅₀ DPPH values. **F)** FICA values.
 630 Different capital letters above the bars indicate significant differences ($p < 0.05$). Results are expressed as mean \pm SEM ($n = 3$).
 631 DPPH: 2,2-diphenyl-1-picrylhydrazyl assay; DW: dry weight; EDTAE: ethylenediaminetetraacetic acid equivalents; F1: fruit
 632 extract from Mora; F2: fruit extract from Puerto Jiménez; FICA: ferrous iron chelating activity assay; FRAP: ferric reducing
 633 antioxidant power assay; GAE: gallic acid equivalents; ORAC: oxygen radical absorbance capacity assay; QE: quercetin
 634 equivalents; SL1: stem and leaf extract from Mora; SL2: stem and leaf extract from Puerto Jiménez; TE: Trolox equivalents; TFC:
 635 total flavonoid content; TPC: total phenolic content.

636
 637 **Figure 6.** Pearson's correlation matrix. **A)** Correlation coefficients (r). **B)** p -values matrix.
 638 DPPH: 2,2-diphenyl-1-picrylhydrazyl assay; FICA: ferrous iron chelating activity assay; FRAP: ferric reducing antioxidant power
 639 assay; ORAC: oxygen radical absorbance capacity assay; TFC: total flavonoid content; TPC: total phenolic content.

640
 641 **Figure 7.** Antinociceptive effect of the stem and leaf extract from Puerto Jiménez (SL2) in the tail flick test in rats.
 642 Results are presented as the mean \pm SEM of the percentage of antinociception ($n = 8$). Statistical significance was determined by
 643 two-way repeated measures ANOVA followed by Dunnett's multiple comparisons test. $*p < 0.05$, $***p < 0.001$ compared to control
 644 (saline solution).

645
 646 **Figure 8.** Anti-inflammatory effect of the stem and leaf extract from Puerto Jiménez (SL2) extract in carrageenan-
 647 induced paw edema in rats.
 648 Results are presented as the mean \pm SEM of the percentage of edema (right hind paw) relative to non-inflamed control (left hind
 649 paw) ($n = 8$). Statistical significance was determined by two-way repeated measures ANOVA followed by Dunnett's multiple
 650 comparison test. $*p < 0.05$ compared to control (saline solution).

651
 652 **Figure 9.** Paw tissue dissected 24 hours after injection of **A)** carrageenan or **B)** saline solution in control groups; **C)**
 653 500 mg/kg, **D)** 250 mg/kg of stem and leaf extract from Puerto Jiménez (SL2); and **E)** 50 mg/kg of indomethacin.
 654 Arrows indicate leukocyte infiltration. Arrowheads indicate congestion and swelling in the tissue. Hematoxylin-eosin staining.
 655 Scale bar = 50 μ m.